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Introduction
Sarcopenia is characterized by progressive and generalized 
loss of skeletal muscle mass and strength, resulting in 
physical disability, poor quality of life, and death (1). While 
often reported in the elderly, loss of muscle mass also occurs 
in patients suffering from congestive heart failure, chronic 
obstructive pulmonary disease, chronic renal failure, or 
cancer (1).
Patients with cancer frequently suffer from sarcopenia (2). 
Sarcopenia in cancer patients is associated with various 
physiological and metabolic events, including systemic 
inflammation and alternations in basal metabolic rate. The 
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prognosis depends not only on the cancer’s aggressiveness 
but also on the patient’s physical condition. Thus, 
sarcopenia can predict poor survival in patients with various 
types of cancers (3-5). Stene et al. showed that up to 71% 
of advanced lung cancer patients undergoing palliative 
chemotherapy suffered from sarcopenia (6) and had poor 
prognoses. On the other hand, patients who undergo 
surgery for lung cancer are often at early stages and have 
good performance status. As a result, the prevalence of 
sarcopenia is lower in these patients [9–56% (7,8)].
Recently, reports focusing on patients with early-stage 
lung cancers are increasing, and they have analyzed the 
effect of sarcopenia on postoperative short- and long-
term outcomes (7-16). Several of these studies indicate 
that sarcopenia may be a useful risk assessment tool 
for postoperative complications as well as a prognostic 
biomarker. However, reports on several factors such as 
pathological stage, surgical procedure, diagnostic tool for 
sarcopenia, and the cut-off value vary. Here, we reviewed 
these various factors and investigated the ability of sarcopenia 
to predict postoperative prognosis and complications in 
lung cancer patients. We present the following article in 
accordance with the PRISMA reporting checklist (available 
at http://dx.doi.org/10.21037/jtd-20-3072).
Methods
Literature research and study selection
We performed a systematic literature search in Medline 
via PubMed (155 hits) on March 1, 2020. No language 
restrictions and no filters were applied to the search. The 
search was performed using the following Mesh terms: 
“sarcopenia” and “lung neoplasm”, “pulmonary neoplasms”, 
“non-small cell lung cancer”, and “lung carcinoma”. The 
abstracts identified by the literature search were screened 
using our inclusion and exclusion criteria. If an abstract was 
judged as potentially relevant, the full text of the publication 
was screened. Selected studies were those that included the 
following contents: (I) sarcopenia assessed by diagnostic 
tools such as DEXA, BIA, or computed tomography (CT), 
(II) patients received surgery for lung cancer, (III) short-
term outcomes (postoperative complications) or long-term 
outcomes [overall survival (OS), disease-free survival (DFS)], 
and (IV) comparing the survival of patients with sarcopenia 
and those without sarcopenia. Studies excluded were those 
that included the following content: (I) patients with small 
cell carcinoma, and (II) papers other than the original 
article. This study did not include experimentation on 
human or animal subjects; thus, institutional review board 
approval was not required.
Data extraction and quality assessment
Two authors independently reviewed the extracted 
information. We obtained clinical data of patients, 
pathological stages, surgical procedures, diagnostic tools 
of sarcopenia, cut off values, OS, DFS, postoperative 
complications and smoking history. If there was a 
discrepancy, the authors discussed and resolved it.
Since the meta-analysis was based on observational 
studies, we used the Newcastle-Ottawa Scale (NOS) as 
previously used (17), which consists of three factors: patient 
selection, comparability of the study groups, and assessment 
of outcomes, to assess the quality and risk-of-bias analysis 
of observational studies. We assigned a score of 0–9 (9 is the 
highest quality) to each observational study (Table 1).
Statistical analysis
A meta-analysis  was performed for perioperative 
complications rate and survival using Review manager 
version 5.3 (The Nordic Cochrane Center, Copenhagen, 
Denmark). Heterogeneity was assessed using I2 statistics 
for describing the proportion of the variability of the 
observed effect estimates that is caused by the heterogeneity 
of studies rather than sampling error. Two-sided P values 
<0.05 were considered statistically significant.
Results
Search results and characteristics of included studies
A flow chart of our search results is shown in Figure 1. A 
total of 155 articles were found in the initial research. We 
found 13 articles for detailed evaluation. However, some 
of those papers were later excluded because there was no 
information on survival. Finally, a total of ten retrospective 
studies on long-term outcomes (7-16), and six studies on 
short-term outcomes (8-11,13,14) were included.
Patients’ characteristics and surgical details are shown 
in Table 1. All studies included were single institutional 
retrospective studies published from 2016 to 2020. The 
total number of patients included in this review was 
2,643 patients, with the number of patients in the reviewed 
articles ranging from 69 to 556 patients. Although the 
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pathological stages were mainly within 0 to 3, twelve 
patients with stage 4 were included in two studies. We 
judged this had little influence on survival since these 
patients were in stage 4 because of oligometastases, and 
these cases were few (12 out of 2,643 cases). Many surgical 
procedures were lobectomies, but limited resections were 
also performed. With the use of the Newcastle-Ottawa 
Scale, one study scored nine stars, three studies scored eight 
stars, four studies scored seven stars and two studies scored 
six stars (Table 1).
Sarcopenia predicts poor prognosis after surgery in patients 
with NSCLC
Table 1 and Figures 2,3 show OS and DFS data. Of the ten 
studies, nine demonstrated that patients with sarcopenia had 
Records identified thorough database searching 
(n =155)
Records after duplicates removed 
(n=0)
Studies included in qualitative synthesis
(n=0)









Patients did not receive surgery
Papers other than original article
(n=142)
No information of prognosis 
after surgery
(n=3)
Figure 1 A flow chart describing the selection process of our study.
Figure 2 Meta-analysis of sarcopenia and overall survival. Forest plots of odds ratio for overall survivals of each study and pooled odds ratio.
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a significantly lower OS rate than those without sarcopenia. 
However, potential heterogeneities were observed in 
these studies. To decrease possible heterogeneities, we 
focused on studies of the same stage of NSCLC or single 
surgical procedures, or the corresponding histology. Three 
studies only focused on stage 1 non-small cell lung cancer, 
with a total of 452 patients. One study with 69 patients, 
exclusively focused on stage 3A NSCLC. These studies 
demonstrated that patients with sarcopenia have a lower 
5-year OS than those without sarcopenia. Two studies, with 
a total of 242 patients, only focused on a single surgical 
procedure, lobectomy. These studies also demonstrated 
that patients with sarcopenia had a lower OS than those 
without sarcopenia. One study showed OS dividing into 
adenocarcinoma and squamous cell carcinoma. They 
demonstrated that sarcopenia was associated with lower OS 
in squamous cell carcinoma patients. On the other hand, 
sarcopenia had no impact on the OS in adenocarcinoma 
patients. A total of 2,191 patients from nine studies were 
included in the meta-analysis, which showed worse OS in 
patients with sarcopenia than those without sarcopenia (odds 
ratio 3.07, 95% CI: 2.45–3.85; Figure 2). We could not 
include two studies (10,16) in this meta-analysis because the 
number of patients with sarcopenia or 5-year OS was not 
indicated.
As for DFS, of the six studies, three demonstrated that 
patients with sarcopenia had a significantly lower DFS 
rate than those without sarcopenia. In these three studies, 
one study focused on stage 3A NSCLC, and two studies 
reported several stages of NSCLC. Total of 1,758 patients 
from six studies were included in the meta-analysis and we 
observed a worse DFS in patients with sarcopenia compared 
to patients without sarcopenia (odds ratio 1.66, 95% CI: 
1.00–2.74; Figure 3).
Sarcopenia predicts postoperative complications in patients 
with NSCLC
Postoperative in-hospital complications are shown in 
Table 2. Of seven studies, two studies demonstrated that 
sarcopenia was significantly associated with postoperative 
complications. Nakamura et al. reported that major 
postoperative complications (Clavien-Dindo grade ≥3) 
occurred more frequently in patients with sarcopenia 
than those without sarcopenia (P=0.036). Kawaguchi et al. 
also reported that postoperative all complications were 
significantly higher in patients with sarcopenia than those 
without sarcopenia. The other four studies also showed that 
patients with sarcopenia tended to experience postoperative 
complications (although not statistically significant). A 
meta-analysis of the postoperative complications from 
six articles that included a total of 1,538 patients was 
performed. This revealed an increased risk of postoperative 
complications for patients with sarcopenia (odds ratio 1.86, 
95% CI: 1.42–2.44; Figure 4).
Optimal diagnostic tool and cut off value for sarcopenia
Sarcopenia was defined using: (I) a sum of skeletal muscles 
at L3 level normalized for height (L3MI, cm2/m2) in 
5 studies; (II) the psoas muscle area at L3 level normalized 
for height (PMI, cm2/m2) in 4 studies; and (III) the total 
muscular mass normalized for height (TMMi, kg/m2) in 1 
study (Table 1). Muscle mass at the L3 level was often used 
as a diagnostic marker because it reflects the skeletal muscle 
mass of the whole body, and it is easy to calculate. The cut-
Figure 3 Meta-analysis of sarcopenia and disease-free survival. Forest plots of odds ratio for disease free survivals of each study and pooled 
odds ratio.
1363Journal of Thoracic Disease, Vol 13, No 3 March 2021
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2021;13(3):1358-1369 | http://dx.doi.org/10.21037/jtd-20-3072
off value varied in studies. L3MI ranged from 43.75 to 55.0 
in male patients and ranged from 38.5 to 41.1 in female 
patients. PMI ranged from 3.70 to 8.71 in male patients 
and ranged from 2.50 to 6.51 in female patients. The cut-
off value of TMMi was 6.49 kg/m2. For L3MI and PMI, the 
lower the cut-off value, the worse the prognosis was. The 
association of sarcopenia and postoperative complications 
was only seen in studies with low cut off levels for 
sarcopenia, or in studies with limited severe complications. 
As a result, L3MI, PMI, TMMi were all optimal diagnostic 
tools for prognosis and tended to become a worse prognosis 
when the cut-off values were low. Furthermore, PMI might 
Table 2 Study characteristics assessed on postoperative complications
Author,  
publication year
Number of patients Surgical procedure
Diagnostic tool 
of sarcopenia








L3MI (cm2) Male: 43.75 cm2/m2; 
female: 41.10 cm2/m2
Sarcopenia: 29%;  






Lobectomy: NA;  
segmentectomy: NA
L3MI (cm2) Male: 49 cm2/m2; 
female: none








lobectomy: 255;  
segmentectomy: 3
L3MI (cm2) Male: 55 cm2/m2; 
female: 39 cm2/m2







Lobectomy: 259;  
limited resection: 69
PMI (cm2/m2) Male: 6.36 cm2/m2; 
female: 3.92 cm2/m2
Sarcopenia: 7%;  






Lobectomy: 259;  
limited resection: 69
L3MI (cm2) Male: 52.4 cm2/m2; 
female: 38.5 cm2/m2





173 (over 75 years)— 
sarcopenia: 32;  
non-sarcopenia: 141
Lobectomy: 173 PMI (cm2/m2) Male: 3.70 cm2/m2; 
female: 2.50 cm2/m2
Sarcopenia: 62.5%;  
non-sarcopenia: 22.7% 
(P<0.001)





lobectomy: 312;  
limited resection: 76 
PMI (cm2/m2) Male: 6.36 cm2/m2; 
female: 3.92 cm2/m2
Sarcopenia: 34.8%;  
non-sarcopenia: 28.5% 
(P=0.19)
Figure 4 Meta-analysis of sarcopenia and postoperative complications. Forest plots of odds ratio for postoperative complications of each 
study and pooled odds ratio.
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predict postoperative complications, when the cut-off value 
was low, or complications limited severity.
The association between sarcopenia and smoking history
Of the ten studies, five reported the smoking history 
of patients (Table 3). Three studies demonstrated that 
sarcopenia was significantly associated with smoking history, 
which included an ever smoker and a current smoker.
Discussion
Sarcopenia and prognosis
In this meta-analysis, we found significantly poor 
postoperative OS and DFS in lung cancer patients with 
sarcopenia. In patients with other types of malignancies, 
sarcopenia also predicted poor survival (3-5). There are 
four reasons for the poor prognosis after surgery in patients 
with sarcopenia. First, sarcopenia itself is a poor prognosis. 
Even if the cancer is completely in remission, the loss of 
muscle mass and strength continues, resulting in physical 
disability and death (1). Second, postoperative complications 
negatively affect prognosis. Patients with sarcopenia tend 
to have postoperative complications. The incidence of 
these complications may strongly predict a poor prognosis 
because physical ability is decreased by complications, 
resulting in poor responses to treatment for not only cancer 
but also other diseases (18). Third, a tumor occurring in 
sarcopenia patients has a more malignant potential than that 
occurring in patients without sarcopenia. As a result, even 
if the pathological stages were the same in both sarcopenia 
and non-sarcopenia patients, the tumor recurrence will be 
frequently observed in sarcopenia patients (11). Finally, the 
most interesting theory is that muscles have a potential tumor 
inhibitory effect via the help of myokines. Skeletal muscles 
have recently been identified as secretory organs, that 
produce myokines, which suppresses the growth of cancer 
cells and are involved in the control of immune cells (19,20). 
For example, muscle-derived myokines, such as Oncostatin 
M, Irisin, and SPARC inhibit the growth of mammary and 
colonic cancer cell in vitro (21,22). In a study using mouse 
models, wheel running exercises induced muscles to release 
IL-6, and this muscle-derived IL-6 mobilize natural killer 
cells to attack tumors and reduces tumor growth (23). 
Furthermore, exercise-induced catecholamines activate 
the Hippo Tumor Suppressor Pathway to reduce tumor 
growth (24). Ozeki et al. reported that high volume muscle 
mass group prolonged DFS after surgery in patients with 
squamous cell carcinoma, which might indicate the tumor 
inhibitory effect via myokines (7).
Sarcopenia and postoperative complications
Our meta-analysis showed an increased risk of postoperative 
complications for patients with sarcopenia. Reports 
on other cancers also indicate an association between 
sarcopenia and postoperative complications. For example, 
gastrointestinal cancer (5,25), hepatopancreaticobiliary 
cancer (5), renal cancer (26) showed a significant increase in 
postoperative complications. Muscle-derived IL-6 inhibits 
TNF production and stimulates the production of the 
anti-inflammatory cytokines IL-1ra and IL-10 (20). 
Therefore, patients with sarcopenia experience a high 
inflammatory response after surgery due to low levels of 
anti-inflammatory cytokines, leading to the development of 
postoperative complications (27).
Based on these results, sarcopenia can be used to identify 
patients at a high risk of postoperative complications, 
and it requires intensive care after surgery. Furthermore, 
surgeons can consider a less-invasive treatment such as 
limited resection or stereotactic irradiation for patients with 
Table 3 The association between sarcopenia and smoking history
Author, publication year Sarcopenia, ever/never smoker Non-sarcopenia, ever/never smoker P value
Suzuki et al., 2016 22 (57.9%)/16 (39.5%) 16 (30.8%)/36 (69.2%) 0.78
Kim et al., 2018 46 (75.4%)/15 (24.6%) 113 (53.6%)/98 (46.4%) 0.003
Nakamura et al., 2018 127 (69.4%)/56 (30.6%) 72 (50.1)/73 (49.9) <0.001
Shinohara et al., 2020 172 (89.9%)/26 (10.1%) 134 (69.4%)/59 (30.6%) <0.001
Philippe et al., 2020 285 (93.6%)/19 (6.4%) 16 (5.3%)/288 (94.7%) 0.91
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sarcopenia (27).
Optimal diagnosis of sarcopenia
We reviewed the diagnostic tools for sarcopenia. The 
European Working Group on Sarcopenia proposed the 
following diagnostic criteria; the presence of low gait speed 
(<0.8 m/s in 4-minute walking test), decreased grip strength 
(<30 kg for men, <20 kg for women), and low muscle mass (1). 
However, these examinations are complex to perform. In 
addition, patients who meet these criteria rarely become 
candidates for surgery because of their poor performance 
statuses. Clinicians need a brief and optimal criterion for 
sarcopenia in order to predict postoperative outcomes for 
NSCLC patients. In our review, five studies used L3MI, four 
studies used PMI, and 1 study used TMMi as diagnostic tools 
for sarcopenia. When considering both the predictability of 
postoperative outcomes and ease of assessment, PMI may be 
feasible. Nakamura et al. (8), and Shinohara et al. (15) used 
6.36 cm2/m2 as the cut-off value for sarcopenia in male patients, 
and 3.92 cm2/m2 in female patients, which were defined 
as <2 SD below the mean PMI of healthy individuals (28). 
Ozeki et al. (7) used 8.71 cm2/m2 in male patients and 
6.51 cm2/m2 in female patients with adenocarcinomas, 
and 7.65 cm2/m2 in male patients and 6.02 cm2/m2 in 
female patients with squamous cell carcinoma. Kawaguchi 
et al. (14) used 3.70 cm2/m2 in male patients and 2.50 cm2/m2 
in female patients; this was defined based on the point of a 
rapid rise in postoperative complications rate.
Based on these results, the optimal cut off values of PMI 
in predicting prognosis are 6.36 cm2/m2 in male patients 
and 3.92 cm2/m2 in female patients, and those used in 
predicting postoperative complications are 3.70 cm2/m2 in 
male patients and 2.50 cm2/m2 in female patients (Table 4).
Therapeutic approach for sarcopenia
It is unclear whether therapeutic intervention for sarcopenia 
prevents postoperative complications or improves OS and 
DFS (29). However, we believe that sarcopenia can become 
a treatment target when trying to improve outcomes in 
NSCLC patients who have undergone surgery. Treatment 
for sarcopenia consists of three approaches: exercise, 
nutrition, and medication (Figure 5).
Physical inactivity increases the risk of development of 
colon (30) and breast cancers (31). Some studies in patients 
with breast cancer have shown the association between 
exercise after cancer diagnosis with improved survival 
(32,33). For example, Chen et al., demonstrated that patients 
who engaged in exercise regularly during the first six 
months after diagnosis had significantly higher OS and DFS 
(HR: 0.62, HR: 0.39, respectively) than those who did not 
exercise (32). However, it is challenging to define “exercise” 
because the type and strength of exercise in studies vary, for 
example walking, gymnastics, body building and traditional 
Chinese exercises. Some reports recommend about 
Table 4 Proposed diagnostic tool and cut-off values of sarcopenia
Outcome Proposed diagnostic tool of sarcopenia Proposed cut off value
Prognosis PMI (cm2/m2) Male: 6.36 cm2/m2; female: 3.92 cm2/m2













Figure 5 Therapeutic approaches for sarcopenia with cancer.
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2.5 hours each week of moderate-intensity physical activity, 
like walking, as exercise (32,33); this may be reasonable 
to perform routinely, and it demonstrated an improving 
prognosis.
Nutrition is also crucial in the treatment of sarcopenia; 
however, there are few reports on nutritional interventions. 
In lung cancer patients, sarcopenia was significantly 
associated with an inadequate intake of protein (34). 
Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), 
and (n-3) fatty acids from fish oil have immune-modulating 
effects and may improve nutritional status in cancer 
patients. These dietary supplements contribute to weight 
maintenance and improvement of walking function (35). 
Two feasibility studies evaluated the multimodal therapy of 
exercise and nutrition. In the Pre-MENAC research, the 
treatment arm consisted of celecoxib 300 mg once daily, 
EPA 2 g/day, training, and nutrition guidance for patients 
with lung and pancreatic cancer. Patients in the treatment 
arm increased in weight more than those in the control 
arm; however, muscle mass was not different between the 
two groups (36). In the MEXTAC study, supplements rich 
in branched-chain amino acids, nutrition guidance, and 
exercise were given to elderly patients with lung cancer, 
which showed proper compliance and safety (37). These 
studies are now in phases 3 and 2, respectively.
Drug therapy can also be used to treat sarcopenia. 
Anamorelin is a selective ghrelin receptor agonist, which 
has anabolic and appetite-enhancing activities. Anamorelin 
significantly increased lean body mass and improved 
appetite and nutritional state in patients with advanced 
lung cancer (38). Espindolol has three pharmacological 
targets: blockade of non-selective β receptors (thus reducing 
catabolism), antagonism of central 5-HT1a receptors 
(potentially reducing fatigue and thermogenesis), and partial 
agonism of β2 receptors (increasing anabolism). Espindolol 
significantly reversed weight loss, and improves lean body 
mass in sarcopenic patients with advanced colorectal 
and lung cancer (39). Myostatin, which inhibits muscle 
hypertrophy, may become the target in the treatment of 
sarcopenia (20). Administration of a myostatin antagonist 
in mice with lung cancer resulted in improvement in body 
muscle weight and agility. Furthermore, tumor volume 
decreased in mice treated with myostatin antagonist 
compared to control mice (40).
Several studies have indicated that smoking may 
contribute to the development of sarcopenia (41). In our 
study, three studies showed the number of patients with 
smoking history were larger in sarcopenia than non-
sarcopenia. So, quitting smoking may become one of the 
therapies for sarcopenia.
These above-described interventions focused on 
patients with advanced cancer. However, we believe that 
interventions for sarcopenia with a resectable lung cancer 
also improve their prognosis. Presently, we propose exercise 
and an improvement of the nutritional status. Muscle 
mass can improve with exercise and the administration of 
nutrients (42), which can improve their prognosis.
Limitations
Several limitations existed in this study. Due to the 
observational design of the included studies, the respective 
meta-analysis may be affected by the biases found in the 
original data. Especially we should be careful for three 
biases. One is a publication bias, which were tested by 
funnel plot for the analysis of OS, DFS and postoperative 
complications,  and these plots had a symmetrical 
appearance (Figure 6). Second, there was heterogeneity in 


















SE (log[OR]) SE (log[OR]) SE (log[OR])
OR OR OR
0.01         0.1            1.0            10           100 0.01         0.1           1.0            10           100 0.01         0.1            1.0            10           100
Figure 6 Funnel plot of the included studies for the analysis of OS, DFS, and postoperative complications. OS, overall survival; DFS, 
disease-free survival.
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the assessment or definition of sarcopenia. In addition, the 
tumor stage and the number of patients involved in the 
analysis of the prognosis in each article was varied. Third, 
our extracted papers are biased toward the Asian countries 
(Japan: 8, Korea: 1, and France: 1).
In conclusion, the results of this systematic review 
and meta-analysis demonstrated that resectable NSCLC 
patients with sarcopenia had significantly worse OS, DFS, 
and frequent development of postoperative complications 
than that of patients without sarcopenia. To diagnose 
sarcopenia, CT-based skeletal muscle measurements, like 
PMI, were useful. In the future, it is necessary to explore 
the mechanisms of sarcopenia and the roles of optimal 





Reporting Checklist: The authors have completed the 
PRISMA reporting checklist. Available at http://dx.doi.
org/10.21037/jtd-20-3072
Peer Review File: Available at http://dx.doi.org/10.21037/jtd-
20-3072
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/jtd-20-3072). The authors have no conflicts 
of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. This study did not 
include experimentation on human or animal subjects; thus, 
institutional review board approval was not required.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: 
European consensus on definition and diagnosis: Report 
of the European Working Group on Sarcopenia in Older 
People. Age Ageing 2010;39:412-23.
2. Fearon KC. Cancer cachexia and fat-muscle physiology. N 
Engl J Med 2011;365:565-7.
3. Harimoto N, Yoshizumi T, Shimokawa M, et al. 
Sarcopenia is a poor prognostic factor following hepatic 
resection in patients aged 70 years and older with 
hepatocellular carcinoma. Hepatol Res 2016;46:1247-55.
4. Villaseñor A, Ballard-Barbash R, Baumgartner K, et al. 
Prevalence and prognostic effect of sarcopenia in breast 
cancer survivors: the HEAL Study. J Cancer Surviv 
2012;6:398-406.
5. Levolger S, van Vugt JL, de Bruin RW, et al. Systematic 
review of sarcopenia in patients operated on for 
gastrointestinal and hepatopancreatobiliary malignancies. 
Br J Surg 2015;102:1448-58.
6. Stene GB, Helbostad JL, Amundsen T, et al. Changes 
in skeletal muscle mass during palliative chemotherapy 
in patients with advanced lung cancer. Acta Oncol 
2015;54:340-8.
7. Ozeki N, Kawaguchi K, Fukui T, et al. Psoas muscle mass 
in patients undergoing lung cancer surgery: a prognostic 
difference between squamous cell carcinoma and 
adenocarcinoma. Int J Clin Oncol 2020;18:020-01624.
8. Nakamura R, Inage Y, Tobita R, et al. Sarcopenia in 
Resected NSCLC: Effect on Postoperative Outcomes. J 
Thorac Oncol 2018;13:895-903.
9. Suzuki Y, Okamoto T, Fujishita T, et al. Clinical 
implications of sarcopenia in patients undergoing complete 
resection for early non-small cell lung cancer. Lung 
Cancer 2016;101:92-7.
10. Tsukioka T, Nishiyama N, Izumi N, et al. Sarcopenia 
is a novel poor prognostic factor in male patients with 
pathological Stage I non-small cell lung cancer. Jpn J Clin 
Oncol 2017;47:363-8.
11. Tsukioka T, Izumi N, Mizuguchi S, et al. Positive 
correlation between sarcopenia and elevation of 
neutrophil/lymphocyte ratio in pathological stage IIIA 
(N2-positive) non-small cell lung cancer patients. Gen 
Thorac Cardiovasc Surg 2018;66:716-22.
12. Shoji F, Matsubara T, Kozuma Y, et al. Relationship Between 
1368 Kawaguchi et al. Sarcopenia and lung cancer surgery
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2021;13(3):1358-1369 | http://dx.doi.org/10.21037/jtd-20-3072
Preoperative Sarcopenia Status and Immuno-nutritional 
Parameters in Patients with Early-stage Non-small Cell 
Lung Cancer. Anticancer Res 2017;37:6997-7003.
13. Kim EY, Lee HY, Kim KW, et al. Preoperative Computed 
Tomography-Determined Sarcopenia and Postoperative 
Outcome After Surgery for Non-Small Cell Lung Cancer. 
Scand J Surg 2018;107:244-51.
14. Kawaguchi Y, Hanaoka J, Ohshio Y, et al. Sarcopenia 
predicts poor postoperative outcome in elderly patients 
with lung cancer. Gen Thorac Cardiovasc Surg 
2019;67:949-54.
15. Shinohara S, Otsuki R, Kobayashi K, et al. Impact of 
Sarcopenia on Surgical Outcomes in Non-small Cell Lung 
Cancer. Ann Surg Oncol 2020;22:020-08224.
16. Icard P, Schussler O, Loi M, et al. Pre-Disease and Pre-
Surgery BMI, Weight Loss and Sarcopenia Impact Survival 
of Resected Lung Cancer Independently of Tumor Stage. 
Cancers (Basel) 2020;12:266.
17. Deng HY, Hou L, Zha P, et al. Sarcopenia is an 
independent unfavorable prognostic factor of non-small 
cell lung cancer after surgical resection: A comprehensive 
systematic review and meta-analysis. Eur J Surg Oncol 
2019;45:728-35.
18. Kawaguchi Y, Hanaoka J, Oshio Y, et al. Decrease in 
performance status after lobectomy mean poor prognosis in 
elderly lung cancer patients. J Thorac Dis 2017;9:1525-30.
19. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: 
skeletal muscle as a secretory organ. Nat Rev Endocrinol 
2012;8:457-65.
20. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory 
therapy for rheumatic diseases-myokine regulation. Nat 
Rev Rheumatol 2015;11:86-97.
21. Hojman P, Dethlefsen C, Brandt C, et al. Exercise-induced 
muscle-derived cytokines inhibit mammary cancer cell 
growth. Am J Physiol Endocrinol Metab 2011;301:E504.
22. Aoi W, Naito Y, Takagi T, et al. A novel myokine, secreted 
protein acidic and rich in cysteine (SPARC), suppresses 
colon tumorigenesis via regular exercise. Gut 2013;62:882-9.
23. Lucia A, Ramirez M. Muscling In on Cancer. N Engl J 
Med 2016;375:892-4.
24. Dethlefsen C, Hansen LS, Lillelund C, et al. Exercise-
Induced Catecholamines Activate the Hippo Tumor 
Suppressor Pathway to Reduce Risks of Breast Cancer 
Development. Cancer Res 2017;77:4894-904.
25. Simonsen C, de Heer P, Bjerre ED, et al. Sarcopenia 
and Postoperative Complication Risk in Gastrointestinal 
Surgical Oncology: A Meta-analysis. Ann Surg 
2018;268:58-69.
26. Peyton CC, Heavner MG, Rague JT, et al. Does 
Sarcopenia Impact Complications and Overall Survival in 
Patients Undergoing Radical Nephrectomy for Stage III 
and IV Kidney Cancer? J Endourol 2016;30:229-36.
27. Reisinger KW, Derikx JP, van Vugt JL, et al. Sarcopenia 
is associated with an increased inflammatory response to 
surgery in colorectal cancer. Clin Nutr 2016;35:924-7.
28. Hamaguchi Y, Kaido T, Okumura S, et al. Proposal 
for new diagnostic criteria for low skeletal muscle mass 
based on computed tomography imaging in Asian adults. 
Nutrition 2016;32:1200-5.
29. Christensen JF, Jones LW, Andersen JL, et al. Muscle 
dysfunction in cancer patients. Ann Oncol 2014;25:947-58.
30. Papadimitriou N, Dimou N, Tsilidis KK, et al. Physical 
activity and risks of breast and colorectal cancer: a 
Mendelian randomisation analysis. Nat Commun 
2020;11:020-14389.
31. Monninkhof EM, Elias SG, Vlems FA, et al. Physical 
activity and breast cancer: a systematic review. 
Epidemiology 2007;18:137-57.
32. Chen X, Lu W, Zheng W, et al. Exercise after diagnosis of 
breast cancer in association with survival. Cancer Prev Res 
(Phila) 2011;4:1409-18.
33. Irwin ML, Smith AW, McTiernan A, et al. Influence of 
pre- and postdiagnosis physical activity on mortality in 
breast cancer survivors: the health, eating, activity, and 
lifestyle study. J Clin Oncol 2008;26:3958-64.
34. Kim EY, Kim K, Kim YS, et al. Prevalence of and Factors 
Associated with Sarcopenia in Korean Cancer Survivors: 
Based on Data Obtained by the Korea National Health 
and Nutrition Examination Survey (KNHANES) 2008-
2011. Nutr Cancer 2017;69:394-401.
35. van der Meij BS, Langius JA, Smit EF, et al. Oral 
nutritional supplements containing (n-3) polyunsaturated 
fatty acids affect the nutritional status of patients with 
stage III non-small cell lung cancer during multimodality 
treatment. J Nutr 2010;140:1774-80.
36. Solheim TS, Laird BJA, Balstad TR, et al. A randomized 
phase II feasibility trial of a multimodal intervention for 
the management of cachexia in lung and pancreatic cancer. 
J Cachexia Sarcopenia Muscle 2017;8:778-88.
37. Naito T, Mitsunaga S, Miura S, et al. Feasibility of 
early multimodal interventions for elderly patients with 
advanced pancreatic and non-small-cell lung cancer. J 
Cachexia Sarcopenia Muscle 2019;10:73-83.
38. Katakami N, Uchino J, Yokoyama T, et al. Anamorelin 
(ONO-7643) for the treatment of patients with non-small 
cell lung cancer and cachexia: Results from a randomized, 
1369Journal of Thoracic Disease, Vol 13, No 3 March 2021
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2021;13(3):1358-1369 | http://dx.doi.org/10.21037/jtd-20-3072
Cite this article as: Kawaguchi Y, Hanaoka J, Ohshio Y, 
Okamoto K, Kaku R, Hayashi K, Shiratori T, Akazawa A. Does 
sarcopenia affect postoperative short- and long-term outcomes 
in patients with lung cancer?—a systematic review and meta-
analysis. J Thorac Dis 2021;13(3):1358-1369. doi: 10.21037/jtd-20-
3072
double-blind, placebo-controlled, multicenter study of 
Japanese patients (ONO-7643-04). Cancer 2018;124:606-16.
39. Stewart Coats AJ, Ho GF, Prabhash K, et al. Espindolol 
for the treatment and prevention of cachexia in patients 
with stage III/IV non-small cell lung cancer or colorectal 
cancer: a randomized, double-blind, placebo-controlled, 
international multicentre phase II study (the ACT-ONE 
trial). J Cachexia Sarcopenia Muscle 2016;7:355-65.
40. Busquets S, Toledo M, Orpi M, et al. Myostatin blockage 
using actRIIB antagonism in mice bearing the Lewis lung 
carcinoma results in the improvement of muscle wasting 
and physical performance. J Cachexia Sarcopenia Muscle 
2012;3:37-43.
41. Steffl M, Bohannon RW, Petr M, et al. Relation between 
cigarette smoking and sarcopenia: meta-analysis. Physiol 
Res 2015;64:419-26.
42. Landi F, Marzetti E, Martone AM, et al. Exercise as a 
remedy for sarcopenia. Curr Opin Clin Nutr Metab Care 
2014;17:25-31.
